Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation

Transplant International

Volumn 29, Issue 1, 2016, Pages 41-50

  Gatault, Philippe ^a,b   Bertrand, Dominique ^c   Büchler, Matthias ^a,b   Colosio, Charlotte ^d   Hurault De Ligny, Bruno ^e   Weestel, Pierre François ^f   Rerolle, Jean Philippe ^g   Thierry, Antoine ^h   Sayegh, Johnny ⁱ   Moulin, Bruno ^j   Snanoudj, Renaud ^k   Rivalan, Joseph ^l   Heng, Anne Elisabeth ^m   Sautenet, Bénédicte ^a   Lebranchu, Yvon ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l RENNES UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

more..

Author keywords

clinical trial; human leukocyte antigen antibody posttransplantation; immunosuppression; kidney transplantation; target of rapamycin inhibitors

Indexed keywords

ANTIBODY; ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; ERYTHROPOIETIN; EVEROLIMUS; HLA ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BOWEN DISEASE; CANCER RISK; CARCINOMATOSIS; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW RISK PATIENT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEINURIA; PULMONARY LYMPHANGITIC CARCINOMATOSIS; RETROSPECTIVE STUDY; SALIVARY GLAND TUMOR; SKIN CANCER; SKIN CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CANCER; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; CAUSE OF DEATH; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GRAFT REJECTION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTOR;

ADULT; ANALYSIS OF VARIANCE; CAUSE OF DEATH; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; SIROLIMUS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84953449537     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12656     Document Type: Article

References (28)

1. Denton MD, Magee CC, Sayegh MH,. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083.
2. Meier-Kriesche H-U, Li S, Gruessner RWG, et al,. Immunosuppression: evolution in practice and trends, 1994-2004: immunosuppression, 1994-2004. Am J Transplant 2006; 6: 1111.
3. Mengel M, Mihatsch M, Halloran PF,. Histological characteristics of calcineurin inhibitor toxicity-there is no such thing as specificity!: histopathology in CNI toxicity. Am J Transplant 2011; 11: 2549.
4. Bröcker V, Schubert V, Scheffner I, et al,. Arteriolar lesions in renal transplant biopsies. Am J Pathol 2012; 180: 1852.
5. El-Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
6. Oberbauer R, Segoloni G, Campistol JM, et al,. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
7. ®, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
8. Lebranchu Y, Snanoudj R, Toupance O, et al,. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the spiesser study: long-term effect of sirolimus or cyclosporine. Am J Transplant 2012; 12: 1801.
9. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation: DSA risk and immunosuppression after KTX. Am J Transplant 2012; 12: 1192.
10. Gatault P, Lebranchu Y,. Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? Transplant Res 2013; 2 (Suppl. 1): S3.
11. Lebranchu Y, Thierry A, Thervet E, et al,. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-Four-year results of the postconcept study: renal function after early CsA-to-SRL conversion. Am J Transplant 2011; 11: 1665.
12. Budde K, Lehner F, Sommerer C, et al,. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study: conversion to everolimus: results at 5 years. Am J Transplant 2015; 15: 119.
13. Silva HT, Yang HC, Meier-Kriesche H-U, et al,. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 2014; 97: 636.
14. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J,. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653.
15. Wiebe C, Gibson IW, Blydt-Hansen TD, et al,. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant: clinical pathologic correlations of de novo DSA. Am J Transplant 2012; 12: 1157.
16. Croze L-E, Tetaz R, Roustit M, et al,. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. Transpl Int 2014; 27: 775.
17. Ruiz San Millán JC, López-Hoyos M, Segundo DS, et al,. Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. Transpl Int 2014; 27: 847.
18. Pascual J, Arns W,. Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients?: letter to the editor. Am J Transplant 2012; 12: 2561.
19. Brokhof MM, Sollinger HW, Hager DR, et al,. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 2014; 9: 612.
20. Rostaing L, Hertig A, Albano L, et al,. Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. Am J Transplant 2015; 15: 1303.
21. Koehl GE, Andrassy J, Guba M, et al,. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319.
22. Geissler EK, Schlitt HJ, Thomas G,. mTOR, cancer and transplantation. Am J Transplant 2008; 8: 2212.
23. Euvrard S, Morelon E, Rostaing L, et al,. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329.
24. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR,. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146.
25. Dantal J, Pohanka E,. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007; 22 (Suppl. 1): i4.
26. Roland M, Gatault P, Al-Najjar A, et al,. Early pulse pressure and low-grade proteinuria as independent long-term risk factors for new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2008; 8: 1719-28.
27. Hjelmesaeth J, Hartmann A, Leivestad T, et al,. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
28. Murakami N, Riella LV, Funakoshi T,. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 2014; 14: 2317.